Vaccines Lead Growth in India’s Pharma Market with 30.1% Surge in February 2026
India’s pharmaceutical market recorded about 11% growth in February 2026, with vaccines emerging as the fastest-growing therapy segment, reflecting rising demand for preventive healthcare.
- By PharmaNews Live Desk
- New Delhi
- Mar 10, 2026
Vaccines emerged as the fastest-growing segment in the Indian Pharmaceutical Market (IPM) in February 2026, recording a 30.1% increase in value, according to market data released by Pharmarack.
The strong performance contributed to the broader expansion of India’s pharmaceutical market, which registered around 11% value growth and 1.3% unit growth during the month, indicating steady demand across multiple therapy categories.
Vaccine segment posts sharp growth
The vaccine therapy segment recorded sales of around ₹220 crore in February 2026, accounting for roughly 1% of the overall Indian Pharmaceutical Market.
Despite its relatively small share of the market, vaccines posted the highest growth among therapy segments, registering 30.1% growth in value and about 44% growth in units, highlighting increased demand for immunisation and preventive healthcare products.
Industry observers note that the growth reflects stronger focus on vaccination programmes and rising awareness around preventive healthcare in India.
Other therapy segments also record gains
Alongside vaccines, several other therapy areas reported strong growth in February.
The “others” therapy category reported ₹162 crore in sales, contributing around 1% of the market, and recorded 24.5% value growth and 23.1% unit growth.
Urology therapies generated ₹370 crore in sales, representing 2% of the market, and posted 14.5% value growth with 6% unit growth during the month.
Meanwhile, anti-neoplastics (oncology therapies) recorded ₹501 crore in sales, accounting for 2% market share, and registered 12.9% value growth along with 21.1% unit growth.
Chronic therapies remain key drivers of the market
Large chronic therapy categories continued to contribute significantly to overall market growth.
According to Pharmarack data, anti-diabetic therapies recorded sales of ₹1,982 crore, accounting for about 10% of the Indian pharmaceutical market, and reported 15.5% value growth with 4.4% unit growth.
Cardiac therapies, the largest therapy category in the market, generated ₹2,937 crore in sales, representing around 14% of the IPM, and recorded 14.8% value growth with 5.8% unit growth.
Indian pharma market records steady expansion
Recent industry data indicates that India’s pharmaceutical market continues to maintain steady momentum. According to Pharmarack figures cited in industry reports, the Indian Pharmaceutical Market recorded approximately 11% year-on-year growth in February 2026.
The growth has been supported by a combination of new product launches, price adjustments and rising demand across therapy segments, particularly in chronic disease treatments and preventive healthcare.
Analysts note that the strong performance across multiple therapy areas highlights the continued expansion of India’s pharmaceutical sector, which remains one of the largest globally and a major supplier of medicines to international markets.